Efalizumab (Raptiva) for plaque psoriasis. EMEA recommends withdrawal of its marketing authorization, FDA issues public health advisory
Raptiva and progressive multifocal leukoencephalopathy : EMEA recommends withdrawal of marketing authorization and FDA recommends monitoring patients.
Efalizumab (Raptiva) and progressive multifocal leukoencephalopathy (PML). New safety information
This is duplicated text of a letter from EMD Serono Canada Inc to health care professionals, available at Health Canada . Dear Health Care Professional, EMD Serono Canada Inc., in collaboration with Health Canada, would like to inform you of important new safety information regarding the risk of serious infections, including progressive multifocal leukoencephalopathy (PML), […]